Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Barrett Esophagus 1

Interventions

fludarabine 8Cyclophosphamide 7Specimen Handling 6Cytarabine 6fludarabine phosphate 5Methotrexate 5venetoclax 4merphos 4Whole-Body Irradiation 4calaspargase pegol 3Tacrolimus 3Spinal Puncture 3Mycophenolic Acid 3Melphalan 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Biopsy 3Asparaginase 3vedolizumab 2prednylidene 2pegaspargase 2deltacortene 2decitabine and cedazuridine drug combination 2blinatumomab 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Rituximab 2Prednisone 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Biphenotypic, Acute × Itraconazole × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡